Spatial immune–stromal organization after neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer: a framework for residual-disease biomarkers

Neoadjuvant chemoimmunotherapy has made the resection specimen a central response readout in resectable non-small-cell lung cancer (NSCLC). Residual viable tumor percentage quantifies treatment effect but does not describe how malignant, immune, stromal, and vascular compartments are organized within the post-treatment tumor bed. Here, we critically review spatial and single-cell studies of treatment-remodeled NSCLC and distinguish direct post-treatment evidence from pretreatment, immunotherapy-only, untreated, and cross-cancer evidence. Recurring but not yet validated observations include mature tertiary lymphoid structures, coordinated B- and T-cell programs, T-cell access to tumor, and selected antigen-presenting myeloid states. Candidate resistance mechanisms include interferon-responsive fibroblast programs, extracellular-matrix barriers, context-dependent myeloid states, and malignant-cell plasticity. Pretreatment BAG3-positive fibroblast neighborhoods provide a related hypothesis whose post-treatment persistence remains unproven. However, cell abundance alone is insufficient, tertiary lymphoid structure density is not consistently associated with pathological complete response, and most proposed spatial metrics lack definitions prespecified and fixed before validation or independent validation. We propose pathology-anchored multiregion sampling, patient-level spatial analysis, explicit handling of tumor-centered metrics that are undefined in tumor-free compartments, and staged assay simplification. This Review provides a pathology-anchored framework for evaluating spatial immune–stromal features as candidate residual-disease biomarkers. Their incremental value beyond pathological burden and circulating tumor DNA requires external validation before biomarker-guided treatment can be tested.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-11-17
DOI
https://doi.org/10.3389/fimmu.2026.1998406
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Spatial immune–stromal organization after neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer: a framework for residual-disease biomarkers

Xing Zhou, Yan Gao, Qianhui Zhou, Chengmeng Liu
6 links
Frontiers in Immunology
Cancer Immunotherapy and Biomarkers
article

Spatial immune–stromal organization after neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer: a framework for residual-disease biomarkers

Xing Zhou, Yan Gao, Qianhui Zhou, Chengmeng Liu
article en

Abstract

Neoadjuvant chemoimmunotherapy has made the resection specimen a central response readout in resectable non-small-cell lung cancer (NSCLC). Residual viable tumor percentage quantifies treatment effect but does not describe how malignant, immune, stromal, and vascular compartments are organized within the post-treatment tumor bed. Here, we critically review spatial and single-cell studies of treatment-remodeled NSCLC and distinguish direct post-treatment evidence from pretreatment, immunotherapy-only, untreated, and cross-cancer evidence. Recurring but not yet validated observations include mature tertiary lymphoid structures, coordinated B- and T-cell programs, T-cell access to tumor, and selected antigen-presenting myeloid states. Candidate resistance mechanisms include interferon-responsive fibroblast programs, extracellular-matrix barriers, context-dependent myeloid states, and malignant-cell plasticity. Pretreatment BAG3-positive fibroblast neighborhoods provide a related hypothesis whose post-treatment persistence remains unproven. However, cell abundance alone is insufficient, tertiary lymphoid structure density is not consistently associated with pathological complete response, and most proposed spatial metrics lack definitions prespecified and fixed before validation or independent validation. We propose pathology-anchored multiregion sampling, patient-level spatial analysis, explicit handling of tumor-centered metrics that are undefined in tumor-free compartments, and staged assay simplification. This Review provides a pathology-anchored framework for evaluating spatial immune–stromal features as candidate residual-disease biomarkers. Their incremental value beyond pathological burden and circulating tumor DNA requires external validation before biomarker-guided treatment can be tested.

Frontiers in ImmunologyVol. 17
Central South University (CN)
Good health and well-being
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon